Defence Appoints New Interim Chief Executive Officer
Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) has announced a leadership change as it transitions from preclinical to clinical stage. Kwin Grauer has been appointed as the interim Chief Executive Officer, replacing Sébastien Plouffe. Grauer, who joined the company's Board of Directors in December 2022, brings over 20 years of experience in operating, buying, and selling small and medium-sized businesses.
Grauer is a CPA, CA with expertise in financing, financial modeling, and corporate restructuring. He has served on the Board of Langara College, including roles as Chair of the Finance and Audit Committee and Board Chair. Plouffe will continue to serve as a director of Defence Therapeutics, with the company acknowledging his contributions to its growth and development.
Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ha annunciato un cambiamento di leadership mentre passa dalla fase preclinica a quella clinica. Kwin Grauer è stato nominato Amministratore Delegato ad interim, sostituendo Sébastien Plouffe. Grauer, che è entrato a far parte del Consiglio di Amministrazione dell'azienda nel dicembre 2022, porta con sé oltre 20 anni di esperienza nella gestione, nell'acquisto e nella vendita di piccole e medie imprese.
Grauer è un CPA, CA con competenze in finanziamenti, modellizzazione finanziaria e ristrutturazione aziendale. Ha ricoperto ruoli nel Consiglio di Langara College, inclusi quelli di Presidente del Comitato Finanze e Audit e Presidente del Consiglio. Plouffe continuerà a servire come direttore di Defence Therapeutics, con l'azienda che riconosce i suoi contributi alla crescita e allo sviluppo della società.
Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ha anunciado un cambio de liderazgo a medida que transita de la etapa preclínica a la clínica. Kwin Grauer ha sido nombrado Director Ejecutivo interino, reemplazando a Sébastien Plouffe. Grauer, quien se unió a la Junta Directiva de la compañía en diciembre de 2022, aporta más de 20 años de experiencia en la operación, compra y venta de pequeñas y medianas empresas.
Grauer es un CPA, CA con experiencia en financiamiento, modelado financiero y reestructuración corporativa. Ha servido en la Junta de Langara College, incluidos roles como Presidente del Comité de Finanzas y Auditoría y Presidente de la Junta. Plouffe continuará sirviendo como director de Defence Therapeutics, con la compañía reconociendo sus contribuciones a su crecimiento y desarrollo.
Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC)는 리더십 변화를 발표했으며, 비임상 단계에서 임상 단계로 전환하고 있습니다. Kwin Grauer가 임시 최고 경영자로 임명되어 Sébastien Plouffe를 대체하게 되었습니다. Grauer는 2022년 12월 회사 이사회에 합류하였으며, 20년 이상의 경험을 갖추고 있습니다. 그는 중소기업의 운영, 인수 및 판매에 대한 방대한 지식을 보유하고 있습니다.
Grauer는 재무, 재무 모델링 및 기업 재구성에 대한 전문성을 가진 CPA, CA입니다. 그는 Langara College 이사회에서 재무 및 감사 위원회 의장 및 이사회 의장으로서 역할을 담당해 왔습니다. Plouffe는 Defence Therapeutics의 이사로 계속 활동할 것이며, 회사는 그의 성장 및 발전에 대한 기여를 인정하고 있습니다.
Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) a annoncé un changement de direction alors qu'elle passe de la phase préclinique à la phase clinique. Kwin Grauer a été nommé directeur général par intérim, remplaçant Sébastien Plouffe. Grauer, qui a rejoint le conseil d'administration de l'entreprise en décembre 2022, apporte plus de 20 ans d'expérience dans la gestion, l'achat et la vente de petites et moyennes entreprises.
Grauer est un CPA, CA avec une expertise en financement, modélisation financière et restructuration d'entreprise. Il a siégé au conseil d'administration du Langara College, occupant des postes de président du comité des finances et de l'audit ainsi que celui de président du conseil. Plouffe continuera à servir comme directeur de Defence Therapeutics, l'entreprise reconnaissant ses contributions à sa croissance et son développement.
Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) hat einen Wechsel in der Führung angekündigt, während das Unternehmen von der präklinischen in die klinische Phase übergeht. Kwin Grauer wurde zum interim Chief Executive Officer ernannt und ersetzt Sébastien Plouffe. Grauer ist seit Dezember 2022 Mitglied des Unternehmensvorstands und bringt über 20 Jahre Erfahrung in der Leitung, dem Kauf und Verkauf von kleinen und mittelständischen Unternehmen mit.
Grauer ist ein CPA, CA mit Fachkenntnissen in Finanzierung, Finanzmodellierung und Unternehmensumstrukturierung. Er hat im Vorstand des Langara College gedient, unter anderem als Vorsitzender des Finanz- und Prüfungsausschusses und Vorsitzender des Vorstands. Plouffe wird weiterhin als Direktor von Defence Therapeutics fungieren, wobei das Unternehmen seine Beiträge zum Wachstum und zur Entwicklung anerkennt.
- Appointment of experienced interim CEO with financial expertise
- Company transitioning from preclinical to clinical stage
- Continuity maintained with former CEO remaining on board as director
- Potential disruption due to leadership change
- Uncertainty associated with an interim CEO appointment
Vancouver, British Columbia--(Newsfile Corp. - August 30, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), announces that Kwin Grauer has been appointed interim Chief Executive Officer replacing Sébastien Plouffe as President and Chief Executive Officer. This change comes as the Company moves from the preclinical stage toward a clinical stage.
Mr. Grauer joined the Board of Directors of the Company in December, 2022. He is a CPA, CA, and has more than 20 years' experience operating, buying and selling small and medium-size businesses. Mr. Grauer is a seasoned professional in financing, financial modeling and corporate restructuring. He has over 10 years of active board work to go along with his business experience and Chartered Professional Accountant Designation. He has served as a Board Member of Langara College, where he was Chair of the Finance and Audit Committee for 5 years and Board Chair for 2 years.
Mr. Plouffe will continue to act as a director of the Company. The Company acknowledges Mr. Plouffe's hard work and dedication over the past few years and thanks him for his exceptional contribution to Defence's growth and development.
About Defence:
Defence Therapeutics is a publicly-traded clinical-stage biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of vaccine antigens or ADCs inside target cells and favoring their processing and activities. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.
For further information:
Kwin Grauer, Interim CEO and Director
P: 604-753-8834
kgrauer@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary Statement Regarding "Forward-Looking" Information
This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/221734
FAQ
Who is the new interim CEO of Defence Therapeutics (DTCFF)?
What is Kwin Grauer's background and experience?
Why did Defence Therapeutics (DTCFF) change its CEO?
What will happen to the former CEO of Defence Therapeutics (DTCFF)?
